Posttranslational modifications of histone deacetylases: Implications for cardiovascular diseases

被引:74
|
作者
Eom, Gwang Hyeon
Kook, Hyun [1 ]
机构
[1] Chonnam Natl Univ, Sch Med, Dept Pharmacol, Kwangju 501746, South Korea
基金
新加坡国家研究基金会;
关键词
Histone deacetylases; Cardiovascular diseases; Posttranslational modifications; Histone deacetylase inhibitors; Therapeutics; SMOOTH-MUSCLE-CELLS; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; CARDIAC MYOCYTE PROLIFERATION; DEPENDENT NUCLEAR EXPORT; GENE-EXPRESSION; CLASS-I; ENDOTHELIAL-CELLS; HYPERTROPHIC RESPONSE; LYSINE ACETYLATION;
D O I
10.1016/j.pharmthera.2014.02.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Posttranslational modification (PTM) is a term that implies dynamic modification of proteins after their translation. PTM is involved not only in homeostasis but also in pathologic conditions related to diverse diseases. Histone deacetylases (HDACs), which are known as transcriptional regulators, are one example of posttranslational modifiers with diverse roles in human pathophysiology, including cardiovascular diseases. In experimental models, HDAC inhibitors are beneficial in supraventricular arrhythmia, myocardial infarction, cardiac remodeling, hypertension, and fibrosis. In addition, HDACs are closely related to other vascular diseases such as neointima formation, atherosclerosis, and vascular calcification. Currently, HDACs are classified into four different classes. The class Ha HDACs work as transcriptional regulators mainly by direct association with other transcription factors to their target binding elements in a phosphorylation-dependent manner. Class I HDACs, by contrast, have much greater enzymatic activity than the class II HDACs and target various non-histone proteins as well as the histone-core complex. Class I HDACs undergo PTMs such as phosphorylation, sumoylation, and S-nitrosylation. Considering the growing evidence for the role of HDACs in cardiovascular diseases, the PTMs of the HDACs themselves as well as HDAC-mediated PTM of their targets should be considered for future potential therapeutic targets. In this review, we discuss 1) the roles of each HDAC in specific cardiovascular diseases and 2) the PTM of HDACs, 3) and the implications of such modifications for cardiovascular diseases. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:168 / 180
页数:13
相关论文
共 50 条
  • [21] Histone deacetylases as targets in autoimmune and autoinflammatory diseases
    Hamminger, Patricia
    Rica, Ramona
    Ellmeier, Wilfried
    ADVANCES IN IMMUNOLOGY, VOL 147, 2020, 147 : 1 - 59
  • [22] Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases
    Sharma, Sorabh
    Sarathlal, K. C.
    Taliyan, Rajeev
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2019, 18 (01) : 11 - 18
  • [23] The role of histone deacetylases in asthma and allergic diseases
    Bhavsar, Pankaj
    Ahmad, Tehireern
    Adcock, Ian M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (03) : 580 - 584
  • [24] Targeting Histone Deacetylases in Diseases: Where Are We?
    Benedetti, Rosaria
    Conte, Mariarosaria
    Altucci, Lucia
    ANTIOXIDANTS & REDOX SIGNALING, 2015, 23 (01) : 99 - 126
  • [25] Role of histone deacetylases and their inhibitors in neurological diseases
    Zhang, Li-Ying
    Zhang, Sen-Yu
    Wen, Ri
    Zhang, Tie-Ning
    Yang, Ni
    PHARMACOLOGICAL RESEARCH, 2024, 208
  • [26] Histone deacetylases as targets for treatment of multiple diseases
    Tang, Jinhua
    Yan, Haidong
    Zhuang, Shougang
    CLINICAL SCIENCE, 2013, 124 (11-12) : 651 - 662
  • [27] Inhibition of Histone Deacetylases in Inflammatory Bowel Diseases
    Rainer Glauben
    Britta Siegmund
    Molecular Medicine, 2011, 17 : 426 - 433
  • [28] Posttranslational Modifications of the Mineralocorticoid Receptor and Cardiovascular Aging
    Gadasheva, Yekatarina
    Nolze, Alexander
    Grossmann, Claudia
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [29] Role of Posttranslational Modifications of Proteins in Cardiovascular Disease
    Liu, Yong-Ping
    Zhang, Tie-Ning
    Wen, Ri
    Liu, Chun-Feng
    Yang, Ni
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [30] Posttranslational modifications in Parkinson's and related diseases
    Pratt, Matthew
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245